

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Manufacturer or supplier's details

Company : MSD
Address : 26 Talavera Road, Talavera Corp Centre, Macquarie Park
New South Wales, 2113 Australia
Telephone : (61)-02-8988-8000
Emergency telephone number : (61)-02-8988-8000
E-mail address : EHSDATASTEWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use


Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1A
Specific target organ toxicity - repeated exposure : Category 2 (Kidney, Parathyroid gland)

GHS label elements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H373 May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P281 Use personal protective equipment as required.

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

Response:

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|---------------------|-------------|-----------------------|
| Cellulose | 9004-34-6 | >= 30 -< 60 |
| Starch | 9005-25-8 | >= 30 -< 60 |
| Olmesartan | 144689-63-4 | >= 10 -< 30 |
| Hydrochlorothiazide | 58-93-5 | >= 1 -< 10 |
| Amlodipine Besylate | 652969-01-2 | < 10 |

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure.

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

Protection of first-aiders : Contact with dust can cause mechanical irritation or drying of the skin.
 : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
 Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
 Nitrogen oxides (NO_x)
 Chlorine compounds
 Sulphur oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
 Use water spray to cool unopened containers.
 Remove undamaged containers from fire area if it is safe to do so.
 Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
 Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
 Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
 Prevent further leakage or spillage if safe to do so.
 Retain and dispose of contaminated wash water.
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
 Local or national regulations may apply to releases and dis-

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Strong oxidizing agents |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|------------|---------|----------------------------------|--|-------|
| | | | | |

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

| | | | | |
|---------------------|--|------------|-------------------------------|----------|
| Cellulose | 9004-34-6 | TWA | 10 mg/m ³ | AU OEL |
| | Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica | | | |
| | | TWA | 10 mg/m ³ | ACGIH |
| Starch | 9005-25-8 | TWA | 10 mg/m ³ | AU OEL |
| | Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica | | | |
| | | TWA | 10 mg/m ³ | ACGIH |
| Olmesartan | 144689-63-4 | TWA | 30 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 300 µg/100 cm ² | Internal |
| Hydrochlorothiazide | 58-93-5 | TWA | 100 µg/m ³ (OEB 2) | Internal |
| Amlodipine Besylate | 652969-01-2 | TWA | 20 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 100 µg/100 cm ² | Internal |

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

| | | |
|--|---|---|
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | Not applicable |
| Relative vapour density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | : | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | : | |
| Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle size | : | No data available |

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

Olmesartan:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg
LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

Hydrochlorothiazide:

Acute oral toxicity : LD50 (Rat): 10,000 mg/kg
LD50 (Mouse): 10,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg
Application Route: Intravenous

LD50 (Dog): 250 mg/kg
Application Route: Intravenous

Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Olmesartan:**

Remarks : No data available

Hydrochlorothiazide:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Olmesartan:**

Species : Rabbit
Result : Moderate eye irritation
Method : Draize Test

Hydrochlorothiazide:

Species : Rabbit
Result : Mild eye irritation

Amlodipine Besylate:

Species : Rabbit
Result : Severe irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

Respiratory sensitisation

Not classified based on available information.

Components:**Olmesartan:**

| | | |
|-----------------|---|-------------------|
| Exposure routes | : | Skin contact |
| Remarks | : | No data available |

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Cellulose:**

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | | Test Type: In vitro mammalian cell gene mutation test Result: negative |
| Genotoxicity in vivo | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative |

Olmesartan:

| | | |
|-------------------------------------|---|---|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | | Test Type: Mutagenicity (in vitro mammalian cytogenetic test) Result: negative |
| | | Test Type: Chromosome aberration test in vitro Test system: Chinese hamster lung cells Result: positive |
| | | Test Type: Mouse Lymphoma Result: negative |
| Genotoxicity in vivo | : | Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative |
| Germ cell mutagenicity - Assessment | : | Weight of evidence does not support classification as a germ cell mutagen. |

Hydrochlorothiazide:

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: Chinese hamster ovary cells
Result: positive

Test Type: in vitro assay
Test system: mouse lymphoma cells
Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: Chinese hamster
Cell type: Bone marrow
Result: negative

Test Type: in vivo assay
Species: Mouse
Cell type: Bone marrow
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Amlodipine Besylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Olmesartan:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

Species : Mouse
Application Route : Oral
Exposure time : 6 Months
Result : negative

Hydrochlorothiazide:

Species : Mouse, female
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse, male
Application Route : Oral
Exposure time : 2 Years
Result : equivocal

Species : Rat, male and female
Application Route : Oral
Exposure time : 2 Years
Result : negative

Amlodipine Besylate:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Olmesartan:

Effects on fertility : Test Type: Fertility
Species: Rat

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

- Application Route: Oral
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility
- Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Dose: 1000 milligram per kilogram
Result: No teratogenic effects
- Test Type: Development
Species: Rabbit
Application Route: Oral
Dose: 1 milligram per kilogram
Result: No teratogenic effects
- Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: \geq 1.6 mg/kg body weight
Symptoms: Malformations were observed., Reduced body weight
Result: Effects on postnatal development
- Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.
- Hydrochlorothiazide:**
- Effects on fertility : Test Type: Fertility
Species: Rat, male and female
Application Route: oral (feed)
Fertility: NOAEL: 4 mg/kg body weight
Result: Effects on fertility
- Test Type: Fertility
Species: Mouse, male and female
Application Route: oral (feed)
Fertility: NOAEL: 100 mg/kg body weight
Result: Effects on fertility
- Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
Result: No teratogenic effects
- Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No teratogenic effects

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|----------------|------------------------------|------------------------------|--|
| Version 1.0 | Revision Date: 07.10.2019 | SDS Number: 4944956-00001 | Date of last issue: - Date of first issue: 07.10.2019 |
|----------------|------------------------------|------------------------------|--|

Amlodipine Besylate:

| | | |
|-------------------------------|---|---|
| Effects on fertility | : | Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Fertility: NOAEL: 10 mg/kg body weight Result: No effects on fertility Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion Fertility: NOAEL: 25 mg/kg body weight Result: No effects on fertility |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: Effects on foetal development Test Type: Embryo-foetal development Species: Rabbit Application Route: Ingestion Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: No effects on foetal development Test Type: Embryo-foetal development Species: Mouse Application Route: Ingestion Developmental Toxicity: LOAEL: 1.6 mg/kg body weight Result: Effects on foetal development Remarks: Maternal toxicity observed. |

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:

| | | |
|---------------|---|---|
| Target Organs | : | Kidney, Parathyroid gland |
| Assessment | : | Causes damage to organs through prolonged or repeated exposure. |

Repeated dose toxicity

Components:

Cellulose:

| | | |
|---------|---|----------------|
| Species | : | Rat |
| NOAEL | : | >= 9,000 mg/kg |

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

Application Route : Ingestion
Exposure time : 90 Days

Olmesartan:

Species : Rat
NOAEL : 2,000 mg/kg
Application Route : Oral
Exposure time : 24 Months
Remarks : No significant adverse effects were reported

Hydrochlorothiazide:

Species : Rat, male and female
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 2 yr
Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female
NOAEL : 300 - 550 mg/kg
Application Route : Oral
Exposure time : 2 yr
Remarks : No significant adverse effects were reported

Species : Dog
: 50 - 200 mg/kg
Application Route : Oral
Exposure time : 9 Months
Target Organs : Parathyroid gland

Amlodipine Besylate:

Species : Rat
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Components:**Hydrochlorothiazide:**

No aspiration toxicity classification

Experience with human exposure**Components:****Olmesartan:**

Eye contact : Symptoms: Eye irritation
Ingestion : Symptoms: hypotension

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

Remarks: May cause harm to the unborn child.
Based on Human Evidence

Hydrochlorothiazide:

| | | |
|-------------|---|---|
| Eye contact | : | Symptoms: Eye irritation |
| Ingestion | : | Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain |

Amlodipine Besylate:

| | | |
|-------------|---|--|
| Eye contact | : | Symptoms: Severe irritation |
| Ingestion | : | Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Oedema, Palpitation |

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

| | | |
|------------------|---|--|
| Toxicity to fish | : | LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials |
|------------------|---|--|

Hydrochlorothiazide:

| | | |
|------------------|---|--|
| Toxicity to fish | : | LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l Exposure time: 96 h |
|------------------|---|--|

| | | |
|---|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 500 mg/l Exposure time: 48 h |
|---|---|--|

Amlodipine Besylate:

| | | |
|------------------|---|--|
| Toxicity to fish | : | LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l Exposure time: 96 h |
|------------------|---|--|

| | | |
|---|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 3.2 mg/l Exposure time: 48 h |
|---|---|--|

| | | |
|----------------------------------|---|--|
| Toxicity to algae/aquatic plants | : | IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
|----------------------------------|---|--|

Persistence and degradability

Components:

Cellulose:

| | | |
|------------------|---|--------------------------------|
| Biodegradability | : | Result: Readily biodegradable. |
|------------------|---|--------------------------------|

Hydrochlorothiazide:

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

Version 1.0 Revision Date: 07.10.2019 SDS Number: 4944956-00001 Date of last issue: -
Date of first issue: 07.10.2019

Stability in water : Hydrolysis: 46.2 %(96 h)

Bioaccumulative potential**Components:****Amlodipine Besylate:**

Partition coefficient: n-octanol/water : log Pow: 3

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under

Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

: not determined

SECTION 16. OTHER INFORMATION

Further information

Revision Date : 07.10.2019
 Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>
 Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
 AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.
 ACGIH / TWA : 8-hour, time-weighted average
 AU OEL / TWA : Exposure standard - time weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods;

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate / Hydrochlorothiazide Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: - |
| 1.0 | 07.10.2019 | 4944956-00001 | Date of first issue: 07.10.2019 |

vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN